Pleomorphic liposarcoma: A cytologic study of five cases

Dodd, Leslie G.; Jiang, Xiaoyin “Sara”; Rao, K. L.N.

doi:10.1002/dc.23148

Cited by 13 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…10 Unlike the other subtypes of liposarcoma, the pleomorphic variant is unique in that it lacks a molecular signature, thus making it difficult to diagnose. 33 It also is often reported to be high grade and may even resemble de-differentiated morphologically. The pleomorphic subtype had the highest proportion of high-grade cases in the SEER database (Grades III & IV ¼ 86.4%), which is similar to other studies.…”

Section: Discussionmentioning

confidence: 99%

Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

Amer

Congiusta

Thomson

et al. 2020

Journal of Clinical Orthopaedics and Trauma

View full text Add to dashboard Cite

Purpose: Liposarcoma (LPS) is a one of the most commonly diagnosed soft tissue sarcomas. Little is known about the epidemiology and prognosis of each subtype. We present an analysis of epidemiology and survival of the subtypes of LPS using a national database. Methods: We queried the Survival Epidemiology, and End Results (SEER) and the Canadian Institute for Clinical Evaluative Sciences (ICES) databases for data on 7 types of LPS. Pearson's chi square was used to determine associations between variables and subtypes. Kaplan-Meier and Cox Regression analyses were performed for two tests: one using SEER data and the other using variables common to both SEER and ICES. Results: The well-differentiated subtype was the most common subtype identified. Metastatic disease was associated with decreased survival across all subtypes and age >35 was associated with decreased survival in well-differentiated and myxoid subtypes. Tumor grade was associated with decreased survival in the well-differentiated, myxoid, mixed, and round cell subtypes. In the secondary analysis, age >35 was associated with decreased survival in the myxoid subtype. Conclusions: The prognosis of liposarcoma differs greatly by subtype. Clinicians should account for patient factors at the time of diagnosis to best navigate treatment of their patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

Amer

Congiusta

Thomson

et al. 2020

Journal of Clinical Orthopaedics and Trauma

View full text Add to dashboard Cite

show abstract

“…Well-differentiated and dedifferentiated liposarcomas show amplification of Murine double minute 2 homolog (MDM 2) and CDK4 genes. [ 6 7 8 9 ] These molecular alterations help in distinguishing well-differentiated liposarcoma from benign adipose tumors and dedifferentiated liposarcomas from other poorly differentiated sarcomas. Myxoid liposarcoma shows DNA damage - inducible transcript 3 (DD1T3) rearrangements.…”

Section: Discussionmentioning

confidence: 99%

“…Myxoid liposarcoma shows DNA damage - inducible transcript 3 (DD1T3) rearrangements. [ 6 7 8 9 ] PLS comprise only 5% of all liposarcoma, do not show any specific aberration, and can be differentiated from myxofibrosarcoma only by the presence of pleomorphic lipoblasts. [ 6 ] However, molecular studies in the present case could not be done due to unavailability and financial constraints.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Large retroperitoneal soft tissue tumor: A cytopathological diagnosis

et al. 2018

View full text Add to dashboard Cite

“… 2 WDLPS are low-grade tumors with more moderate behavior, whereas DDLPS, MLPS and PLPS are high-grade tumors with greater aggressiveness, recurrence and metastasis potential. 3 – 5 At present, surgical resection is still the only method to cure RLPS; however, surgical resection cannot resolve the problem of local recurrence and often becomes not applicable for advanced-stage patients. In addition, different subtypes of liposarcoma have heterogeneous biological behaviors and inconsistent responses to radiotherapy and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

<p>Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance</p>

Zhang¹,

Liang²,

Cui³

et al. 2020

OTT

View full text Add to dashboard Cite

Background: Retroperitoneal liposarcoma (RLPS) is a rare tumor with high recurrence rate. Ribonucleotide reductase small subunit M2 (RRM2) protein is essential for DNA synthesis and replication. Our previous study has demonstrated that RRM2 downregulation inhibited the proliferation of RLPS cells, but further association between RRM2 and RLPS and relevant mechanisms remains to be explored. Methods: RRM2 expression was evaluated in RLPS tumor tissues and cell lines by using real-time PCR and immunohistochemical analysis. The effect of RRM2 downregulation on cell proliferation, apoptosis, cell cycle, cell migration and invasion was tested by lentivirus. The effect of RRM2 inhibition on tumor growth in vivo was assessed by using patientderived tumor xenograft (PDX) of RLPS and RRM2 inhibitor. The underlying mechanisms of RRM2 in RLPS were explored by protein microarray and Western blotting. Results: The results showed that RRM2 mRNA expression was higher in RLPS tissues than in normal fatty tissues (P<0.001). RRM2 expression was higher in the dedifferentiated, myxoid/round cell, and pleomorphic subtypes (P=0.027), and it was also higher in the highgrade RLPS tissues compared to that in the low-grade RLPS tissues (P=0.004). There was no correlation between RRM2 expression and overall survival (OS) or disease-free survival (DFS) in this group of RLPS patients (P>0.05). RRM2 downregulation inhibited cell proliferation, promoted cell apoptosis, facilitated cell cycle from G1 phase to S phase and inhibited cell migration and invasion. Inhibition of RRM2 suppressed tumor growth in NOD/ SCID mice. Protein microarray and Western blot verification showed that activity of Akt/ mammalian target of rapamycin/eukaryotic translation initiation factor 4E binding protein 1 (Akt/mTOR/4EBP1) pathway was downregulated along with RRM2 downregulation. Conclusion: RRM2 was overexpressed in RLPS tissues, and downregulation of RRM2 could inhibit RLPS progression. In addition, suppression of RRM2 is expected to be a promising treatment for RLPS patients.

show abstract

Pleomorphic liposarcoma: A cytologic study of five cases

Cited by 13 publications

References 39 publications

Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

Epidemiology and survival of liposarcoma and its subtypes: A dual database analysis

Large retroperitoneal soft tissue tumor: A cytopathological diagnosis

<p>Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance</p>

Contact Info

Product

Resources

About